Mirikizumab
Mirikizumab is a monoclonal antibody medication used to treat inflammatory conditions by targeting the IL-23 pathway. It works by binding to the p19 subunit of IL-23, blocking its interaction with receptors and reducing inflammatory responses. This medication is primarily used for autoimmune disorders affecting the skin and gastrointestinal tract.
Mirikizumab is an immunosuppressant monoclonal antibody that targets IL-23 to treat inflammatory conditions like psoriasis and inflammatory bowel disease.
Key facts at a glance
- ATC
- L04AC24
- RxNorm
- 2668384
- Generic
- Mirikizumab
- Class
- atc-l04
- Brands
- Omvoh
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
6 groupspregnancy
all trimestersavoid if possible
use only if benefits outweigh potential risks to fetus; discontinue if pregnancy occurs unless clearly needed
regular prenatal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
consider continuing if needed for maternal condition; weigh benefits against potential infant exposure
monitor infant for infections
Use with caution and monitor for adverse effects.
geriatric
elderly 65 and olderno dose adjustment required
no dosage adjustment needed based on age; monitor for infections
standard clinical monitoring
pediatric_age
pediatric under 18not established
not approved for use in pediatric patients; safety and efficacy not established
not applicable
renal_impairment
severe renal impairmentno dose adjustment required
no dosage adjustment needed; monoclonal antibodies not renally cleared
standard clinical monitoring
hepatic_impairment
mild to moderate hepatic impairmentno dose adjustment required
no dosage adjustment needed; monoclonal antibodies metabolized via proteolytic degradation
standard clinical monitoring
Statistics and clinical data
FDA approval year
First FDA approval for ulcerative colitis
Drug class
Biologic immunotherapy targeting interleukin-23
Common uses
Approved therapeutic indications
Mechanism of action
Pharmacodynamic mechanism
Mirikizumab is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, as well as moderately to severely active ulcerative colitis. It is administered as a subcutaneous injection.
Mirikizumab is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of the cytokine IL-23. By blocking IL-23 from binding to its receptor, it inhibits the downstream inflammatory signaling that drives the differentiation, expansion, and survival of inflammatory cells involved in mucosal inflammation.
As an immunosuppressant, mirikizumab may increase the risk of infections, including serious infections. It is contraindicated in patients with known hypersensitivity to the active substance or any excipients. Patients should be monitored for signs of infection during treatment and for a period after discontinuation.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy